A new research paper was published in Oncotarget entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma."
Health Professionals
Color blindness and differentiating between choroidal melanoma and choroidal nevus
A few studies have highlighted the differences between healthcare professionals with CVD and those with normal color vision.
TIL Therapy Plus IL-2 as Second-Line Treatment for Advanced Melanoma
Tumor-infiltrating lymphocyte (TIL) therapy in combination with high-dose interleukin-2 (IL-2) should be considered as a second-line treatment of choice for patients with advanced melanoma who have received anti-PD-(L)1 therapy, according to researchers.
BNT111 Plus Cemiplimab Generates Responses in Unresectable Stage III/IV Melanoma
BioNTech has announced positive topline findings from an ongoing phase 2 trial (NCT04526899) evaluating the investigational mRNA cancer immunotherapy BNT111 in combination with cemiplimab (Libtayo) for patients with unresectable stage III or IV melanoma who experienced disease progression following anti-PD-(L)1 therapy.